Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion {equilateral_black_triangle}

Active Ingredient:
blinatumomab
Company:  
Amgen Ltd See contact details
ATC code: 
L01FX07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

BLINCYTO Guide for Nurses

{healthcare_pro_orange} For Healthcare Professionals

Administrative update: Added links to Nurse's Guide Website

{external_link}

BLINCYTO Guide for Nurses Website

{healthcare_pro_orange} For Healthcare Professionals

Interactive website version of the Nurse's Guide

{pdf_link}

BLINCYTO Guide for Patients and Caregivers

Updated following the ICANS approval

{pdf_link}

BLINCYTO Patient Alert Card

Updated following the ICANS approval

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Amgen Ltd
Company image
Address
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, UK
Telephone
+44 (0)1223 420 305
Fax
+44 (0)1223 426 314
Medical Information Direct Line
+44 (0)1223 436 441
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1223 426 314